Kazia Therapeutics Ltd ADR (KZIA)

$3.64 +0.22 (6.51%)
Market Cap 3.44M
Revenue (ttm) 1.63M
Net Income (ttm) -17.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,077.30%
Debt to Equity Ratio -0.06
Volume 87,700
Avg Vol 45,638
Day's Range N/A - N/A
Shares Out 1.01M
Stochastic %K 60%
Beta 2.28
Analysts Strong Sell
Price Target $57.50

Latest News on KZIA

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Mar 31, 2025, 7:30 AM EDT - 26 days ago

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Jan 30, 2025, 7:30 AM EST - 3 months ago

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Jan 14, 2025, 4:00 PM EST - 3 months ago

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Jan 10, 2025, 9:58 AM EST - 3 months ago

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

Dec 31, 2024, 12:34 PM EST - 4 months ago

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Dec 31, 2024, 8:00 AM EST - 4 months ago

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Dec 11, 2024, 8:00 AM EST - 4 months ago

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Nov 4, 2024, 7:30 AM EST - 6 months ago

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Oct 2, 2024, 8:45 AM EDT - 7 months ago

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

Sep 23, 2024, 8:30 AM EDT - 7 months ago

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Sep 12, 2024, 7:30 AM EDT - 8 months ago

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment

Jul 10, 2024, 12:24 PM EDT - 10 months ago

Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Jul 10, 2024, 7:30 AM EDT - 10 months ago

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Jun 27, 2024, 8:15 AM EDT - 10 months ago

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

May 23, 2024, 2:41 PM EDT - 1 year ago

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

May 1, 2024, 8:45 AM EDT - 1 year ago

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Mar 21, 2024, 8:52 AM EDT - 1 year ago

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Kazia announces presentation of new data at AACR Annual Meeting

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Kazia announces presentation of new data at AACR Annual Meeting

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Feb 21, 2024, 7:30 AM EST - 1 year ago

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Jan 18, 2024, 7:30 AM EST - 1 year ago

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Dec 5, 2023, 6:02 PM EST - 1 year ago

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Kazia Therapeutics Announces $2 Million Registered Direct Offering

Dec 1, 2023, 8:00 AM EST - 1 year ago

Kazia Therapeutics Announces $2 Million Registered Direct Offering

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

Nov 29, 2023, 7:01 AM EST - 1 year ago

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Nov 21, 2023, 7:30 AM EST - 1 year ago

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Nov 20, 2023, 4:30 PM EST - 1 year ago

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Nov 15, 2023, 8:30 AM EST - 1 year ago

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA

Nov 10, 2023, 7:01 AM EST - 1 year ago

KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA

KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA

Nov 1, 2023, 7:01 AM EDT - 1 year ago

KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY

Oct 23, 2023, 7:01 AM EDT - 1 year ago

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY

Kazia announces voluntary delisting from ASX

Oct 11, 2023, 7:01 AM EDT - 1 year ago

Kazia announces voluntary delisting from ASX

KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS

Oct 5, 2023, 7:01 AM EDT - 1 year ago

KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS

KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

Sep 29, 2023, 7:01 AM EDT - 1 year ago

KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY

Jul 6, 2023, 7:00 AM EDT - 1 year ago

KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY

KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

Jun 8, 2023, 7:00 AM EDT - 2 years ago

KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

May 25, 2023, 7:01 AM EDT - 2 years ago

KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT

KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Apr 14, 2023, 7:01 AM EDT - 2 years ago

KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

Apr 4, 2023, 7:00 AM EDT - 2 years ago

KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

Jan 16, 2023, 7:01 AM EST - 2 years ago

KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies

Dec 19, 2022, 9:00 PM EST - 2 years ago

Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies

KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING

Dec 15, 2022, 7:01 AM EST - 2 years ago

KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING

Kazia Therapeutics (KZIA): EVT801 Data Published in Peer-Reviewed Journal

Dec 9, 2022, 5:40 AM EST - 2 years ago

Kazia Therapeutics (KZIA): EVT801 Data Published in Peer-Reviewed Journal

COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL

Dec 1, 2022, 7:01 AM EST - 2 years ago

COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL

KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

Nov 9, 2022, 7:00 AM EST - 2 years ago

KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates

Nov 2, 2022, 7:10 AM EDT - 2 years ago

Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates

KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA

Oct 27, 2022, 7:00 AM EDT - 2 years ago

KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA

PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY

Oct 6, 2022, 8:00 AM EDT - 2 years ago

PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY

KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE

Sep 9, 2022, 8:00 AM EDT - 2 years ago

KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE

KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO

Sep 8, 2022, 8:30 AM EDT - 2 years ago

KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO

Kazia Therapeutics (KZIA): Doubling Down on Clinical Development

Sep 7, 2022, 10:35 AM EDT - 2 years ago

Kazia Therapeutics (KZIA): Doubling Down on Clinical Development

KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES

Aug 5, 2022, 8:40 AM EDT - 2 years ago

KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES